LifeArc and PrecisionLife target ALS

Not-for-profit UK medical research organization LifeArc and techbio company PrecisionLife have announced a strategic R&D collaboration to accelerate the discovery and development of targeted treatments for amyotrophic lateral sclerosis (ALS), a disease also known as motor neurone disease.

The collaboration will accelerate pioneering findings by PrecisionLife, working with the Motor Neurone Disease Association and leading clinicians at King’s College London and the University of Sheffield, to analyze genotyped patient data and find novel genetic insights into the disease.

Promise of derisked development